Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Next Wave Of M&A Sweeps In, Bringing Novel Approaches That May Be Here To Stay

Executive Summary

The first half of 2014 has been one wild M&A ride for the pharma industry, with some of the most valuable deals pharma has seen in years proposed. They have involved everything from asset swaps to mega-mergers, activist investors and tax inversion strategies, suggesting industry is testing different approaches to address a similar challenge: increasing pressure from payers to reduce health care and drug spending.

You may also be interested in...



Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends

Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.

Pfizer and BioNTech To Initiate COVID-19 Vaccine Clinical Trials In April

The two companies announced more details about their COVID-19 vaccine development plan, including a $185m upfront payment and $113m equity investment from Pfizer.

Sage Makes Deep Cuts, Axing 53% Of The Workforce, As It Reins In Zulresso

The company will cut 340 positions, primarily affecting Zulresso commercial operations, to save $170m, after announcing it will need to run new trials to support the regulatory plan for zuranolone.

Topics

Related Companies

UsernamePublicRestriction

Register

PS056134

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel